Filing Flows › Comparisons › CGON vs OTLK
CG Oncology vs Outlook Therapeutics: CGON and OTLK compared
CG Oncology is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.5M for Outlook Therapeutics (Q3 FY25).
Where the money goes: CGON and OTLK
CG Oncology (CGON) · Q3 2026
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart follows the revenue to costs, profit and cash.
Outlook Therapeutics (OTLK) · Q3 FY25
Outlook Therapeutics, Q3 FY25: revenue $1.5M, net loss $20.2M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| CG Oncology (CGON) | Outlook Therapeutics (OTLK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 FY25 |
| Revenue | $1.6M | $1.5M |
| Revenue growth, Y/Y | -4% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$56.9M | −$20.2M |
| Operating cash flow | −$47.7M | −$11.9M |
Questions
Which is bigger, CG Oncology or Outlook Therapeutics?
CG Oncology is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.5M for Outlook Therapeutics (Q3 FY25).
More: CG Oncology earnings · how CG Oncology makes money · Outlook Therapeutics earnings · how Outlook Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 14, 2025). Fiscal quarters can end on different dates. Not investment advice.